The last strategic committee of the FAME project conducted in collaboration between BIOASTER and MaaT Pharma took place Friday, April 10, 2020.

Through this collaboration, BIOASTER and MaaT Pharma illustrate once again the dynamism and quality of the French ecosystem in the promising field of microbiome, as well as the success of this type of partnership:

–        the completion of a CIFRE PhD thesis under the co-supervision of Vincent THOMAS (Head of Microbiome Program, BIOASTER) and Joël DORE (MaaT Pharma co-founder, Research Director at INRAE)

–        the production of important results in the field of fermentation, in compliance with the standards in force (United States Pharmacopeial Convention)

–        the isolation of new bacterial strains and their characterization (BIOASTER’s ANOXIC platform)

–        the submission of scientific papers and patents

A great step forward and a collaboration that will continue through new projects.

Thanks to the BIOASTER and MaaT Pharma teams involved in the FAME project!

MaaT Pharma (Lyon, France) is a pioneer and leading French microbiome company, specialized in the development of disease-specific microbiome restoration biotherapeutics.  MaaT Pharma was the first microbiome SME to trust BIOASTER in the setting up and execution of a large-scale collaborative research project on strategic axes for the company.

www.maatpharma.com

www.bioaster.org